miRNAs and cell-cycle control in ESCs

N. Bot

DOI: https://doi.org/10.1038/NCB2544

IF: 21.3

2012-06-29

Nature Cell Biology

Abstract:

What problem does this paper attempt to address?

Fecal Microbiota Transplantation in Inflammatory Bowel Disease

Adrian Boicean,Victoria Birlutiu,Cristian Ichim,Paula Anderco,Sabrina Birsan

DOI: https://doi.org/10.3390/biomedicines11041016

IF: 4.757

2023-03-28

Biomedicines

Abstract:Inflammatory bowel diseases represent a complex array of diseases of incompletely known etiology that led to gastrointestinal tract chronic inflammation. In inflammatory bowel disease, a promising method of treatment is represented by fecal microbiota transplantation (FMT), FMT has shown its increasing effectiveness and safety in recent years for recurrent CDI; moreover, it showed real clinical benefits in treating SARS-CoV-2 and CDI co-infection. Crohn's disease and ulcerative colitis are characterized by immune dysregulation, resulting in digestive tract damage caused by immune responses. Most current therapeutic strategies are associated with high costs and many adverse effects by directly targeting the immune response, so modifying the microbial environment by FMT offers an alternative approach that could indirectly influence the host's immune system in a safe way. Studies outline the endoscopic and clinical improvements in UC and CD in FMT patients versus control groups. This review outlines the multiple benefits of FMT in the case of IBD by improving patients unbalanced gut, therefore improving endoscopic and clinical symptomatology. We aim to emphasize the clinical importance and benefits of FMT in order to prevent flares or complications of IBD and to highlight that further validation is needed for establishing a clinical protocol for FMT in IBD.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Fecal transplantation for treatment of inflammatory bowel disease.

Aamer Imdad,Maribeth R Nicholson,Emily E Tanner‐Smith,Joseph P Zackular,Oscar G Gomez‐Duarte,Dawn B Beaulieu,Sari Acra,Emily E Tanner-Smith,Oscar G Gomez-Duarte

DOI: https://doi.org/10.1002/14651858.CD012774.pub2

IF: 8.4

2019-10-04

Cochrane Database of Systematic Reviews

Abstract:Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal tract that is thought to be associated with a complex interplay between microbes and the immune system, leading to an abnormal inflammatory response in genetically susceptible individuals. Dysbiosis, characterized by the alteration of the composition of the resident commensal bacteria in a host compared to healthy individuals, is thought to play a major role in the pathogenesis of ulcerative colitis (UC) and Crohn's disease (CD), two subtypes of IBD. There is growing interest to correct the underlying dysbiosis through the use of fecal microbiota transplantation (FMT) for the treatment of IBD.

medicine, general & internal
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Manuele Biazzo,Gabriele Deidda

DOI: https://doi.org/10.3390/jcm11144119

2022-07-15

Abstract:The human body is home to a variety of micro-organisms. Most of these microbial communities reside in the gut and are referred to as gut microbiota. Over the last decades, compelling evidence showed that a number of human pathologies are associated with microbiota dysbiosis, thereby suggesting that the reinstatement of physiological microflora balance and composition might ameliorate the clinical symptoms. Among possible microbiota-targeted interventions, pre/pro-biotics supplementations were shown to provide effective results, but the main limitation remains in the limited microbial species available as probiotics. Differently, fecal microbiota transplantation involves the transplantation of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's gut microbial composition aiming to confer a health benefit. Firstly used in the 4th century in traditional Chinese medicine, nowadays, it has been exploited so far to treat recurrent Clostridioides difficile infections, but accumulating data coming from a number of clinical trials clearly indicate that fecal microbiota transplantation may also carry the therapeutic potential for a number of other conditions ranging from gastrointestinal to liver diseases, from cancer to inflammatory, infectious, autoimmune diseases and brain disorders, obesity, and metabolic syndrome. In this review, we will summarize the commonly used preparation and delivery methods, comprehensively review the evidence obtained in clinical trials in different human conditions and discuss the variability in the results and the pivotal importance of donor selection. The final aim is to stimulate discussion and open new therapeutic perspectives among experts in the use of fecal microbiota transplantation not only in Clostridioides difficile infection but as one of the first strategies to be used to ameliorate a number of human conditions.
Microbiota Therapy in Inflammatory Bowel Disease

Luc Biedermann,Andrea Kreienbühl,Gerhard Rogler

DOI: https://doi.org/10.1159/000536254

2024-01-29

Visceral Medicine

Abstract:Background: In both Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD) the immune reaction is – at least partially – directed against components of the luminal microbiota of the gut. These immune responses as well as other factors contribute to a phenomenon frequently described as “dysbiosis” meaning an alteration of the composition of the colonic microbiota. To improve the dysbiosis and to restore the normal composition of the colonic microbiota, fecal microbiota transplantation (FMT) has been tested as a therapeutic option to induce and maintain remission in IBD patients. Summary: This review will first discuss changes in the composition of the intestinal microbiota found in IBD patients and second the therapeutic potential of microbiological interventions for the treatment of these patients. FMT has been studied in several clinical trials in both, CD and UC. Reported results and subsequent meta-analyses indicate that FMT may be effective to induce remission in UC. However, the optimal route of FMT, the necessary number of administrations and the question whether life bacteria of freshly prepared stool is more effective than frozen are still unclear. Concepts associated with an optimization of FMT such as the “super donor concept” or the “consortia-approach” will be discussed to illustrate open questions and difficulties associated with microbiota therapy in IBD. Key Messages: The microbiota composition in IBD patients shows significant alterations compared to healthy individuals termed as “dysbiosis”. FMT and other therapeutic approaches to modify the microbiota composition have been studied in clinical trials in recent years. Efficacy has been shown in UC; however, many questions with respect to the optimization of microbiota therapy remain to be answered.

gastroenterology & hepatology,surgery
Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Alexa R. Weingarden,Byron P. Vaughn

DOI: https://doi.org/10.1080/19490976.2017.1290757

IF: 12.2

2017-02-10

Gut Microbes

Abstract:Inflammatory bowel disease (IBD) is a complex set of diseases that lead to chronic inflammation in the gastrointestinal tract. Although the etiology of IBD is not fully understood, it is well-known that the intestinal microbiota is associated with the development and maintenance of IBD. Manipulation of the gut microbiota, therefore, may represent a target for IBD therapy. Fecal microbiota transplantation (FMT), where fecal microbiota from a healthy donor is transplanted into a patient's GI tract, is already a successful therapy for Clostridium difficile infection. FMT is currently being explored as a potential therapy for IBD as well. In this review, the associations between the gut microbiota and IBD and the emerging data on FMT for IBD will be discussed.

gastroenterology & hepatology,microbiology
Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation

Rongrong Wu,Rui Xiong,Yan Li,Junru Chen,Ru Yan

DOI: https://doi.org/10.1016/j.jaut.2023.103062

IF: 14.511

2023-05-28

Journal of Autoimmunity

Abstract:Gut dysbiosis has been associated with inflammatory bowel disease (IBD), one of the most common gastrointestinal diseases. The microbial communities play essential roles in host physiology, with profound effects on immune homeostasis, directly or via their metabolites and/or components. There are increasing clinical trials applying fecal microbiota transplantation (FMT) with Crohn's disease (CD) and ulcerative colitis (UC). The restoration of dysbiotic gut microbiome is considered as one of the mechanisms of FMT therapy. In this work, latest advances in the alterations in gut microbiome and metabolome features in IBD patients and experimental mechanistic understanding on their contribution to the immune dysfunction were reviewed. Then, the therapeutic outcomes of FMT on IBD were summarized based on clinical remission, endoscopic remission and histological remission of 27 clinical trials retrieved from PubMed which have been registered on ClinicalTrials.gov with the results been published in the past 10 years. Although FMT is established as an effective therapy for both subtypes of IBD, the promising outcomes are not always achieved. Among the 27 studies, only 11 studies performed gut microbiome profiling, 5 reported immune response alterations and 3 carried out metabolome analysis. Generally, FMT partially restored typical changes in IBD, resulted in increased α-diversity and species richness in responders and similar but less pronounced shifts of patient microbial and metabolomics profiles toward donor profiles. Measurements of immune responses to FMT mainly focused on T cells and revealed divergent effects on pro-/anti-inflammatory functions. The very limited information and the extremely confounding factors in the designs of the FMT trials significantly hindered a reasonable conclusion on the mechanistic involvement of gut microbiota and metabolites in clinical outcomes and an analysis of the inconsistencies.

immunology
The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis

Adam Saleh,Shyon Parsa,Manuel Garza,Eamonn M.M. Quigley,Bincy P. Abraham

DOI: https://doi.org/10.1159/000529591

2023-03-02

Digestive Diseases

Abstract:Background: Considerable research supports an important role for the microbiome and/or microbiome–host immune system interactions in the pathogenesis of inflammatory bowel disease (IBD). Consequently, microbiota-modulating interventions, such as fecal microbiota transplantation (FMT), have attracted interest in the management of IBD, including ulcerative colitis (UC). Summary: While the clinical response to FMT in UC has varied between different studies, results to date may offer guidance towards optimal use of FMT. Thus, increased microbiome biodiversity, the presence of short-chain fatty acid producing bacteria, Clostridium Cluster IV and XIVa, Odoribacter splanchnicus and reduced levels of Caudovirales bacteriophages have been identified as characteristics of the donor microbiome that predict a positive response. However, inconsistency in FMT protocol between studies confounds their interpretation, so it is currently difficult to predict response and premature to recommend FMT, in general, as a treatment for UC. Additional randomized controlled trials designed based on previous findings and employing a standardized protocol are needed to define the role of FMT in the management of UC. Key Messages: There is a well-developed rationale for the use of microbiome-modulating interventions in UC. Despite variations in study protocol and limitations in study design that confound their interpretation, FMT seems to benefit patients with UC, overall. Available data identify factors predicting FMT response and should lead to the development of optimal FMT study protocols.
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease

Xiaochen Zhang,Dai Ishikawa,Toshifumi Ohkusa,Shinji Fukuda,Akihito Nagahara

DOI: https://doi.org/10.3389/fmed.2022.1068567

IF: 3.9

2022-12-02

Frontiers in Medicine

Abstract:Inflammatory bowel disease (IBD) is a chronic intestinal mucosal inflammatory disease with complex etiology. Traditional anti-inflammatory treatment regimens have yielded unsatisfactory results. As research continues to deepen, it has been found that the gut microbiota of patients with IBD is generally altered. The presence of microorganisms in the human gastrointestinal tract is inextricably linked to the regulation of health and disease. Disruption of the microbiotic balance of microbiota in the gastrointestinal tract is called dysbiosis, which leads to disease. Therefore, in recent years, the exploration of therapeutic methods to restore the homeostasis of the gut microbiota has attracted attention. Moreover, the use of the well-established fecal microbiota transplantation (FMT) regimen for the treatment of Clostridioides difficile infection has attracted the interest of IBD researchers. Therefore, there are an increasing number of clinical studies regarding FMT for IBD treatment. However, a series of questions regarding FMT in the treatment of IBD warrants further investigation and discussion. By reviewing published studies, this review explored hot topics such as the efficacy, safety, and administration protocol flow of FMT in the treatment of IBD. Different administration protocols have generally shown reassuring results with significant efficacy and safety. However, the FMT treatment regimen needs to be further optimized. We believe that in the future, individual customized or standard FMT implementation will further enhance the relevance of FMT in the treatment of IBD.

medicine, general & internal
Current and future microbiome-based therapies in inflammatory bowel disease

Jonathan A Montrose,Satya Kurada,Monika Fischer

DOI: https://doi.org/10.1097/MOG.0000000000001027

2024-07-01

Abstract:Purpose of review: The role of the microbiome and dysbiosis is increasingly recognized in the pathogenesis of inflammatory bowel disease (IBD). Intestinal microbiota transplant (IMT), previously termed fecal microbiota transplant has demonstrated efficacy in restoring a healthy microbiome and promoting gut health in recurrent Clostridioides difficile infection. Several randomized trials (RCTs) highlighted IMT's potential in treating ulcerative colitis, while smaller studies reported on its application in managing Crohn's disease and pouchitis. Recent findings: This review delves into the current understanding of dysbiosis in IBD, highlighting the distinctions in the microbiota of patients with IBD compared to healthy controls. It explores the mechanisms by which IMT can restore a healthy microbiome and provides a focused analysis of recent RCTs using IMT for inducing and maintaining remission in IBD. Lastly, we discuss the current knowledge gaps that limit its widespread use. Summary: The body of evidence supporting the use of IMT in IBD is growing. The lack of a standardized protocol impedes its application beyond clinical trials. Further research is needed to identify patient profile and disease phenotypes that benefit from IMT, to delineate key donor characteristics, optimize the delivery route, dosage, and frequency.
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Loris Riccardo Lopetuso,Sara Deleu,Lihi Godny,Valentina Petito,Pierluigi Puca,Federica Facciotti,Harry Sokol,Gianluca Ianiro,Luca Masucci,Maria Abreu,Iris Dotan,Samuel Paul Costello,Ailsa Hart,Tariq H Iqbal,Sudarshan Paramsothy,Maurizio Sanguinetti,Silvio Danese,Herbert Tilg,Fabio Cominelli,Theresa T Pizarro,Alessandro Armuzzi,Giovanni Cammarota,Antonio Gasbarrini,Séverine Vermeire,Franco Scaldaferri

DOI: https://doi.org/10.1136/gutjnl-2023-329948

IF: 24.5

2023-06-20

Gut

Abstract:Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on the following key issues related to FMT in IBD: (A) pathogenesis and rationale, (B) donor selection and biobanking, (C) FMT practices and (D) consideration of future studies and perspectives. Statements were evaluated and voted on by all members using an electronic Delphi process, culminating in a plenary consensus conference and generation of proposed guidelines. Results and conclusions Our group has provided specific statements and recommendations, based on best available evidence, with the end goal of providing guidance and general criteria required to promote FMT as a recognised strategy for the treatment of IBD.

gastroenterology & hepatology
Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition

Claudia Burrello,Maria Rita Giuffrè,Angeli Dominique Macandog,Angelica Diaz-Basabe,Fulvia Milena Cribiù,Gianluca Lopez,Francesca Borgo,Luigi Nezi,Flavio Caprioli,Maurizio Vecchi,Federica Facciotti

DOI: https://doi.org/10.3390/cells8060517

IF: 6

2019-05-28

Cells

Abstract:Different gastrointestinal disorders, including inflammatory bowel diseases (IBD), have been linked to alterations of the gut microbiota composition, namely dysbiosis. Fecal microbiota transplantation (FMT) is considered an encouraging therapeutic approach for ulcerative colitis patients, mostly as a consequence of normobiosis restoration. We recently showed that therapeutic effects of FMT during acute experimental colitis are linked to functional modulation of the mucosal immune system and of the gut microbiota composition. Here we analysed the effects of therapeutic FMT administration during chronic experimental colitis, a condition more similar to that of IBD patients, on immune-mediated mucosal inflammatory pathways. Mucus and feces from normobiotic donors were orally administered to mice with established chronic Dextran Sodium Sulphate (DSS)-induced colitis. Immunophenotypes and functions of infiltrating colonic immune cells were evaluated by cytofluorimetric analysis. Compositional differences in the intestinal microbiome were analyzed by 16S rRNA sequencing. Therapeutic FMT in mice undergoing chronic intestinal inflammation was capable to decrease colonic inflammation by modulating the expression of pro-inflammatory genes, antimicrobial peptides, and mucins. Innate and adaptive mucosal immune cells manifested a reduced pro-inflammatory profile in FMT-treated mice. Finally, restoration of a normobiotic core ecology contributed to the resolution of inflammation. Thus, FMT is capable of controlling chronic intestinal experimental colitis by inducing a concerted activation of anti-inflammatory immune pathways, mechanistically supporting the positive results of FMT treatment reported in ulcerative colitis patients.

cell biology
Fecal microbiota transplantation: current challenges and future landscapes

Abbas Yadegar,Haggai Bar-Yoseph,Tanya Marie Monaghan,Sepideh Pakpour,Andrea Severino,Ed J. Kuijper,Wiep Klaas Smits,Elisabeth M. Terveer,Sukanya Neupane,Ali Nabavi-Rad,Javad Sadeghi,Giovanni Cammarota,Gianluca Ianiro,Estello Nap-Hill,Dickson Leung,Karen Wong,Dina Kao

DOI: https://doi.org/10.1128/cmr.00060-22

IF: 36.8

2024-05-09

Clinical Microbiology Reviews

Abstract:SUMMARY Given the importance of gut microbial homeostasis in maintaining health, there has been considerable interest in developing innovative therapeutic strategies for restoring gut microbiota. One such approach, fecal microbiota transplantation (FMT), is the main “whole gut microbiome replacement” strategy and has been integrated into clinical practice guidelines for treating recurrent Clostridioides difficile infection (rCDI). Furthermore, the potential application of FMT in other indications such as inflammatory bowel disease (IBD), metabolic syndrome, and solid tumor malignancies is an area of intense interest and active research. However, the complex and variable nature of FMT makes it challenging to address its precise functionality and to assess clinical efficacy and safety in different disease contexts. In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of its procedural and administration aspects. The clinical applications of FMT in children and cancer immunotherapy are also described. We focus on data from human studies in IBD in contrast with rCDI to delineate the putative mechanisms of this treatment in IBD as a model, including colonization resistance and functional restoration through bacterial engraftment, modulating effects of virome/phageome, gut metabolome and host interactions, and immunoregulatory actions of FMT. Furthermore, we comprehensively review omics technologies, metagenomic approaches, and bioinformatics pipelines to characterize complex microbial communities and discuss their limitations. FMT regulatory challenges, ethical considerations, and pharmacomicrobiomics are also highlighted to shed light on future development of tailored microbiome-based therapeutics.

microbiology
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

Sergii Tkach,Andrii Dorofeyev,Iurii Kuzenko,Nadiya Boyko,Tetyana Falalyeyeva,Luigi Boccuto,Emidio Scarpellini,Nazarii Kobyliak,Ludovico Abenavoli

DOI: https://doi.org/10.3390/medicina58010084

2022-01-06

Medicina

Abstract:The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, it is not surprising that gut microbiota modification methods may constitute a therapy whose potential has not yet been fully investigated. In this regard, the most interesting method is thought to be fecal microbiota transplantation, which consists of the simultaneous replacement of the intestinal microbiota of a sick recipient with fecal material from a healthy donor. This review summarizes the most interesting findings on the application of fecal microbiota transplantation in gastrointestinal and extraintestinal pathologies.
Features of Gut Microbiome Associated with Responses to Fecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review

Jindong Zhang,Yangyang Guo,Liping Duan

DOI: https://doi.org/10.3389/fmed.2022.773105

IF: 3.9

2022-01-01

Frontiers in Medicine

Abstract:Fecal microbiota transplantation (FMT) has been seen as a novel treatment for inflammatory bowel disease (IBD). The results on microbial alterations and their relationship to treatment efficacy are varied among studies. We performed a systematic review to explore the association between microbial features and therapy outcomes. We searched PubMed, Web of Science, Embase, and Cochrane Library databases from inception to November 2020. Studies that investigated the efficacy of FMT and baseline microbial features or dynamic alteration of the microbiome during FMT were included. The methodological quality of the included cohort studies and randomized controlled trials (RCTs) was assessed using the Newcastle-Ottawa Scale (NOS) and the Cochrane risk of bias tool, respectively. A total of 30 studies were included in the analysis. Compared to non-responders, the microbial structure of patients who responded to FMT had a higher similarity to that of their donors after FMT. Donors of responders (R-d) and non-responders (NR-d) had different microbial taxa, but the results were inconsistent. After FMT, several beneficial short-chain fatty acids- (SCFA-) producing taxa, such as Faecalibacterium, Eubacterium, Roseburia, and species belonging to them, were enriched in responders, while pathogenic bacteria (Escherichia coli and Escherichia-Shigella) belonging to the phylum Proteobacteria were decreased. Alterations of microbial functional genes and metabolites were also observed. In conclusion, the response to FMT was associated with the gut microbiota and their metabolites. The pre-FMT microbial features of recipients, the comparison of pre- and post-FMT microbiota, and the relationship between recipients and donors at baseline should be further investigated using uniform and standardized methods.
The role of the fecal microbiota in inflammatory bowel disease

Rami Khalaf,Martina Sciberras,Pierre Ellul

DOI: https://doi.org/10.1097/MEG.0000000000002818

2024-11-01

Abstract:The understanding of the potential role of the microbiota in the pathogenesis of inflammatory bowel disease (IBD) is ever-evolving. Traditionally, the management of IBD has involved medical therapy and/or surgical intervention. IBD can be characterized by gut microbiome alterations through various pathological processes. Various studies delve into nontraditional methods such as probiotics and fecal microbiota transplant and their potential therapeutic effects. Fecal microbiota transplant involves the delivery of a balanced composition of gut microorganisms into an affected patient via multiple possible routes and methods, while probiotics consist of live microorganisms given via the oral route. At present, neither method is considered first-line treatment, however, fecal microbiota transplant has shown potential success in inducing and maintaining remission in ulcerative colitis. In a study by Kruis and colleagues, Escherichia coli Nissle 1917 was considered to be equivalent to mesalamine in mild ulcerative colitis. Alteration of the microbiome in the management of Crohn's disease is less well defined. Furthermore, variation in the clinical usefulness of 5-aminosalicylic acid medication has been attributed, in part, to its acetylation and inactivation by gut microbes. In summary, our understanding of the microbiome's role is continually advancing, with the possibility of paving the way for personalized medicine based on the microbiome.
Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Pufang Tan,Xiaogang Li,Jun Shen,Qi Feng

DOI: https://doi.org/10.3389/fphar.2020.574533

IF: 5.6

2020-09-18

Frontiers in Pharmacology

Abstract:Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.

pharmacology & pharmacy
Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

Rohma Ghani,Despoina Chrysostomou,Lauren A Roberts,Madhumitha Pandiaraja,Julian R. Marchesi,Benjamin H. Mullish

DOI: https://doi.org/10.1080/19490976.2024.2423026

IF: 12.2

2024-11-07

Gut Microbes

Abstract:Faecal/intestinal microbiota transplant (FMT/IMT) is an efficacious treatment option for recurrent Clostridioides difficile infection, which has prompted substantial interest in FMT's potential role in the management of a much broader range of diseases associated with the gut microbiome. Despite its promise, the success rates of FMT in these other settings have been variable. This review critically evaluates the current evidence on the impact of clinical, biological, and procedural factors upon the therapeutic efficacy of FMT, and identifies areas that remain nebulous. Due to some of these factors, the optimal therapeutic approach remains unclear; for example, the preferred timing of FMT administration in a heavily antibiotic-exposed hematopoietic cell transplant recipient is not standardized, with arguments that can be made in alternate directions. We explore how these factors may impact upon more informed selection of donors, potential matching of donors to recipients, and aspects of clinical care of FMT recipients. This includes consideration of how gut microbiome composition and functionality may strategically inform donor selection criteria. Furthermore, we review how the most productive advances within the FMT space are those where clinical and translational outcomes are assessed together, and where this model has been used productively in recent years to better understand the contribution of the gut microbiome to human disease, and start the process toward development of more targeted microbiome therapeutics.

gastroenterology & hepatology,microbiology
Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease

Alexander N. Levy,Jessica R. Allegretti

DOI: https://doi.org/10.1177/1756284819836893

2019-01-01

Therapeutic Advances in Gastroenterology

Abstract:Fecal microbiota transplantation (FMT) has changed the treatment landscape of Clostridium difficile infection (CDI). Emerging evidence has shown that FMT can also be an effective and safe treatment strategy in CDI with underlying inflammatory bowel disease (IBD). Recently, randomized controlled trials of FMT in ulcerative colitis support its expanding role in restoring gut homeostasis in this disease. However, heterogeneous study designs leave several questions yet to be answered, including how to best position this novel therapy in the treatment approach of Crohn’s disease and pouchitis. Additional studies are needed to validate whether FMT can assume a complementary role in the standard treatment of IBD.

gastroenterology & hepatology
Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives

Cong Dai,Yu-Hong Huang,Min Jiang

DOI: https://doi.org/10.3748/wjg.v30.i16.2179

IF: 5.374

2024-04-28

World Journal of Gastroenterology

Abstract:In this editorial we comment on the article published in the recent issue of the World journal of Gastroenterology . We focus specifically on the mechanisms un-derlying the effects of fecal microbiota transplantation (FMT) for irritable bowel syndrome (IBS), the factors which affect the outcomes of FMT in IBS patients, and challenges. FMT has emerged as a efficacious intervention for clostridium difficile infection and holds promise as a therapeutic modality for IBS. The utilization of FMT in the treatment of IBS has undergone scrutiny in numerous randomized controlled trials, yielding divergent outcomes. The current frontier in this field seeks to elucidate these variations, underscore the existing knowledge gaps that necessitate exploration, and provide a guideline for successful FMT imple-mentation in IBS patients. At the same time, the application of FMT as a treatment for IBS confronts several challenges.

gastroenterology & hepatology
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease

Catherine M. Andary,Kait F. Al,John A. Chmiel,Shaeley Gibbons,Brendan A. Daisley,Seema Nair Parvathy,Saman Maleki Vareki,Dawn M.E. Bowdish,Michael S. Silverman,Jeremy P. Burton

DOI: https://doi.org/10.1016/j.molmed.2023.12.005

2024-01-10

Trends in Molecular Medicine

Abstract:Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent Clostridioides difficile infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term 'dysbiosis' has been used to describe microbial imbalances in relation to disease, but this traditional definition fails to consider the complex cross-feeding networks that define the stability of the microbiome. Emerging research transitions toward the targeted restoration of microbial functional networks in treating different diseases. In this review, we explore potential mechanisms responsible for the efficacy of FMT and future therapeutic applications, while revisiting definitions of 'dysbiosis' in favor of functional network restoration in rCDI, inflammatory bowel diseases (IBDs), metabolic diseases, and cancer.

biochemistry & molecular biology,cell biology,medicine, research & experimental

miRNAs and cell-cycle control in ESCs

Fecal Microbiota Transplantation in Inflammatory Bowel Disease

Fecal transplantation for treatment of inflammatory bowel disease.

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases

Microbiota Therapy in Inflammatory Bowel Disease

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation

The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis

Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease

Current and future microbiome-based therapies in inflammatory bowel disease

The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition

Fecal microbiota transplantation: current challenges and future landscapes

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

Features of Gut Microbiome Associated with Responses to Fecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review

The role of the fecal microbiota in inflammatory bowel disease

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease

Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives

Dissecting mechanisms of fecal microbiota transplantation efficacy in disease